Clinical trials are at the heart of health innovation, whether for new drugs or medical devices. Yet their length and complexity have become a major bottleneck, slowing down R&D productivity and delaying patient access to innovation. According to a recent McKinsey analysis, the biopharmaceutical industry could significantly boost competitiveness by adopting new evaluation methods and accelerating clinical processes.
But this reflection is not limited to pharmaceuticals. Medical devices, particularly digital health technologies, face the same challenges: how to evaluate fast-moving technologies within regulatory frameworks that often evolve more slowly?
Clinical trials: the bottleneck of innovation
On average, it takes 7 to 10 years for a new drug to move from preclinical research to market access. Development costs are skyrocketing, sometimes reaching $2.5 billion for a single molecule. This unsustainable situation is putting pressure on an industry already facing growing healthcare demands.
Clinical trials are the main choke point. Increasingly complex protocols, difficulties in patient recruitment, and time-consuming data collection and analysis all contribute to slowing down innovation. For Europe to remain competitive, rethinking this stage has become a strategic priority.
How to accelerate drug development through clinical trials?
Several levers can shorten the clinical evaluation timeline while ensuring scientific rigor:
- Decentralized clinical trials (DCTs): enabling patients to participate from home using connected devices and remote monitoring, reducing the burden of travel.
- Artificial intelligence and big data: faster identification of eligible patients, optimized trial design, and real-time data analysis.
- New trial methodologies: adaptive trials, multi-arm platforms, and broader use of real-world data to complement results.
- Organizational agility: simplified governance and better coordination between pharmaceutical companies, CROs, and health authorities.
Pilot studies have already shown that these innovations can significantly reduce trial duration without compromising scientific quality.
Medical devices: similar challenges with unique dynamics
For medical devices, the situation is comparable but with specific constraints. Innovation cycles are often much faster than in drug development. For a digital or AI-based device, waiting six or seven years for evaluation may mean the technology is obsolete by the time it reaches the market.
The European Medical Device Regulation (MDR 2017/745) has strengthened clinical requirements with a focus on safety and transparency. However, in practice, this regulatory tightening has extended timelines, slowing patient access to certain innovations.
Clinical trials for medical devices must therefore strike a balance: robust enough to guarantee safety and efficacy, but proportionate so as not to block fast-moving technologies that could improve patient care.
Why the United States and Asia are moving faster
International comparisons highlight a growing competitiveness gap.
- In the United States, the FDA offers several accelerated pathways, such as Fast Track, Breakthrough Therapy, and Accelerated Approval. These mechanisms reduce authorization timelines, especially for innovative drugs and high-impact devices. The FDA’s more flexible, proportionate approach adapts to the specificities of each technology.
- In Asia, countries like China, South Korea, and Singapore have set up one-stop shops and simplified frameworks to attract international clinical trials. These initiatives speed up decisions, reduce administrative burdens, and increase investor appeal.
As a result, clinical trials in these regions are often faster, giving patients earlier access to innovation. Without reform, Europe risks falling behind.
Europe: towards regulatory convergence?
On the drug side, the Clinical Trials Regulation (EU 536/2014) aims to harmonize and streamline trials, introducing the CTIS (Clinical Trial Information System) portal to reduce administrative delays. For medical devices, however, the MDR 2017/745 has tightened requirements on safety, traceability, and transparency—sometimes multiplying timelines fivefold.
Better coordination between these frameworks could ease innovation. Beyond regulatory simplification, it is a question of international competitiveness: without convergence, the U.S. and Asia will remain more attractive for strategic trials and investment.
Conclusion: making clinical trials faster, safer, and more efficient
Whether for an innovative drug or a next-generation medical device, the challenge is the same: to make clinical trials faster, more efficient, and just as safe.
Digitalization, artificial intelligence, real-world evidence, and regulatory harmonization are key levers. If Europe can successfully activate them, it will not only preserve its competitiveness but also ensure that patients gain faster access to life-changing innovations.
Useful links
- EMA – Clinical Trials Regulation (EU 536/2014)
- Commission européenne – Règlement dispositifs médicaux 2017/745
- McKinsey – Accelerating clinical trials to improve biopharma R&D productivity
